Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Inclusion Criteria: * Untreated, histologically confirmed, KRAS wild type, resectable gastric or esophageal adenocarcinoma * T2-4 NX M0 disease * ECOG performance status 0-1 * adequate hematological status * adequate renal function * adequate hepatic function * adequate metabolic function Exclusion Criteria: * pregnant or breast feeding women * previous malignancy other than gastric cancer in the last 5 years except curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix * arterial or venous thromboembolism within 6 months before enrollment * clinically significant cardiovascular disease within 1 year before enrollment * history of interstitial lung disease